Walleye Capital LLC Boosts Stock Holdings in Bruker Corporation $BRKR

Walleye Capital LLC lifted its position in Bruker Corporation (NASDAQ:BRKR) by 6,405.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,116 shares of the medical research company’s stock after acquiring an additional 13,899 shares during the quarter. Walleye Capital LLC’s holdings in Bruker were worth $510,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Royal Bank of Canada boosted its holdings in Bruker by 8.3% during the first quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company’s stock worth $5,148,000 after purchasing an additional 9,501 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in Bruker in the 1st quarter valued at about $262,000. Goldman Sachs Group Inc. increased its stake in Bruker by 107.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company’s stock valued at $61,162,000 after buying an additional 758,301 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Bruker by 2.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 366,204 shares of the medical research company’s stock worth $15,285,000 after buying an additional 9,235 shares in the last quarter. Finally, Focus Partners Wealth lifted its position in shares of Bruker by 115.0% during the 1st quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company’s stock worth $469,000 after buying an additional 6,008 shares in the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Stock Down 2.7%

BRKR opened at $60.45 on Friday. The company has a quick ratio of 0.72, a current ratio of 1.55 and a debt-to-equity ratio of 0.67. The stock has a market cap of $9.20 billion, a price-to-earnings ratio of -251.88, a PEG ratio of 1.99 and a beta of 1.29. Bruker Corporation has a twelve month low of $28.53 and a twelve month high of $64.54. The company’s 50-day moving average price is $56.32 and its two-hundred day moving average price is $46.32.

Bruker (NASDAQ:BRKR) last released its earnings results on Wednesday, May 6th. The medical research company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.23 by $0.08. The firm had revenue of $823.40 million during the quarter, compared to the consensus estimate of $795.62 million. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The company’s revenue was up 2.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.47 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, equities analysts expect that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, July 7th. Shareholders of record on Monday, June 22nd were given a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend was Monday, June 22nd. Bruker’s dividend payout ratio (DPR) is currently -83.33%.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on BRKR shares. JPMorgan Chase & Co. boosted their target price on Bruker from $55.00 to $65.00 and gave the stock an “overweight” rating in a research note on Monday, June 8th. Barclays increased their price target on Bruker from $53.00 to $60.00 and gave the company an “overweight” rating in a research report on Wednesday, June 24th. Stifel Nicolaus set a $45.00 price target on Bruker in a report on Friday, May 8th. Weiss Ratings raised Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, June 3rd. Finally, Wall Street Zen upgraded Bruker from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Bruker presently has a consensus rating of “Hold” and a consensus price target of $56.79.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.